- Home
- COMM vs MESO Comparison
COMM vs MESO Comparison
Compare COMM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COMM
- MESO
- Stock Information
- Founded
- COMM 1976
- MESO 2004
- Country
- COMM United States
- MESO Australia
- Employees
- COMM N/A
- MESO N/A
- Industry
- COMM Radio And Television Broadcasting And Communications Equipment
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COMM Technology
- MESO Health Care
- Exchange
- COMM Nasdaq
- MESO Nasdaq
- Market Cap
- COMM 1.1B
- MESO 1.1B
- IPO Year
- COMM 2013
- MESO N/A
- Fundamental
- Price
- COMM $4.38
- MESO $10.18
- Analyst Decision
- COMM Hold
- MESO Strong Buy
- Analyst Count
- COMM 5
- MESO 4
- Target Price
- COMM $2.50
- MESO $11.50
- AVG Volume (30 Days)
- COMM 5.2M
- MESO 215.6K
- Earning Date
- COMM 11-07-2024
- MESO 08-28-2024
- Dividend Yield
- COMM N/A
- MESO N/A
- EPS Growth
- COMM N/A
- MESO N/A
- EPS
- COMM N/A
- MESO N/A
- Revenue
- COMM $5,183,800,000.00
- MESO $5,902,000.00
- Revenue This Year
- COMM N/A
- MESO $66.05
- Revenue Next Year
- COMM $2.94
- MESO $348.27
- P/E Ratio
- COMM N/A
- MESO N/A
- Revenue Growth
- COMM 21.78
- MESO N/A
- 52 Week Low
- COMM $0.86
- MESO $1.61
- 52 Week High
- COMM $7.19
- MESO $12.18
- Technical
- Relative Strength Index (RSI)
- COMM 36.08
- MESO 54.91
- Support Level
- COMM $4.07
- MESO $10.00
- Resistance Level
- COMM $4.58
- MESO $10.98
- Average True Range (ATR)
- COMM 0.47
- MESO 0.59
- MACD
- COMM -0.15
- MESO 0.06
- Stochastic Oscillator
- COMM 9.94
- MESO 47.92
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. They have operating segments, which excludes our Home segment: Connectivity and Cable Solutions (CCS), Outdoor Wireless Networks (OWN), Networking, Intelligent Cellular and Security Solutions (NICS) and Access Network Solutions (ANS).
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.